SCHEMBL347925

SCHEMBL347925

COC(=O)c1coc(CN2CCN(C(=O)OC(C)(C)C)CC2)n1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CACNA1G O43497 5/20 0.55
KCNH2 Q12809 2/20 0.54
HRH3 Q9Y5N1 2/20 0.46
GSK3B P49841 2/20 0.44
ACKR3 P25106 3/20 0.41
NR1H2 P55055 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CHRM2 P08172 1/20 0.40
CHRM4 P08173 1/20 0.40
CHRM1 P11229 1/20 0.40
CHRM3 P20309 1/20 0.40
VEGFA P15692 1/20 0.39
EGLN1 Q9GZT9 1/20 0.39
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
GPR119 Q8TDV5 1/20 0.39
PIK3CD O00329 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7427115 0.81 HRH3 (0.57) CACNA1GKCNH2HRH3GSK3BALDH1A1
SCHEMBL7421852 0.80 HRH3 (0.59) CACNA1GKCNH2HRH3GSK3BALDH1A1
SCHEMBL10055070 0.78 CACNA1G (0.53) CACNA1GKCNH2HRH3GSK3BALDH1A1
SCHEMBL22166944 0.77 ACHE (0.48) HRH3ACKR3NR1H2ALDH1A1CHRM2
SCHEMBL7430392 0.76 CACNA1G (0.61) CACNA1GKCNH2GSK3BALDH1A1
SCHEMBL29132216 0.76 NR1H2 (0.45) ACKR3NR1H2ALDH1A1CHRM2CHRM4
SCHEMBL2579312 0.76 GPR119 (0.46) ALDH1A1GPR119
SCHEMBL17271685 0.76 FAAH (0.53) CHRM2CHRM4CHRM1CHRM3VEGFA
SCHEMBL17481790 0.76 ACKR3 (0.42) ACKR3NR1H2ALDH1A1CHRM2CHRM4
SCHEMBL22166943 0.76 VEGFA (0.44) ACKR3NR1H2ALDH1A1VEGFAEGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8759352-B2 1-(4-ureidobenzoyl)piperazine derivatives MERCK SHARP & DOHME B.V. (NL) 2014-06-24 US disclosed
EP-2318368-B1 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES MERCK SHARP & DOHME (NL) 2013-10-16 EP disclosed
US-20120015958-A1 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES N.V. ORGANON (NL) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015958-A1 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES NPC1, ABCB11, NPC1L1 CACNA1G 2942/4885KCNH2 2332/4885HRH3 1328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.